Dowpharma agrees Pfenex expression technology licence deal with Iomai

Published: 12-Jul-2005

Dowpharma has set up a license agreement with private biopharmaceutical company Iomai Corporation in the US for its Pfenex expression technology, a Pseudomonas-based technology that accelerates speed to market for vaccines and biotherapeutics.


Dowpharma has set up a license agreement with private biopharmaceutical company Iomai Corporation in the US for its Pfenex expression technology, a Pseudomonas-based technology that accelerates speed to market for vaccines and biotherapeutics.

Under the agreement, Iomai will use the Pfenex expression technology for production of heat labile enterotoxin (LT), a key component of its transcutaneous immunisation platform technology for the delivery of vaccines to the skin.

Iomai will initially produce LT for use as a vaccine to treat enterotoxigenic Escherichia coli (ETEC) - the most common cause of acute diarrhoea among travellers to developing countries.

Stanley Erck, president and ceo at Iomai, said: 'We believe that Pfenex will enable us to increase the expression of our protein and deliver higher yields to support the advancement of our ETEC vaccine towards regulatory approval.'

You may also like